Nyxoah has announced the continued expansion of its commercial footprint in the Middle East, following the first successful Genio implant in Abu Dhabi in September 2025.

The Middle East is home to world-class healthcare systems, renowned Key Opinion Leaders (KOLs), and Centres of Excellence (CoEs). Nyxoah has partnered with these institutions spread over Dubai, Kuwait and Abu Dhabi to broaden access to Genio and improve outcomes for patients living with Obstructive Sleep Apnea (OSA) who are unable to tolerate CPAP.

Olivier Taelman, Chief Executive Officer (CEO), Nyxoah, commented, "The Middle East represents an important and growing market for Nyxoah, and we are delighted to see this momentum since our initial launch in the region earlier this year. Expanding from Dubai into Kuwait and Abu Dhabi allows us to bring the unique, patient-centric Genio solution to more individuals suffering from Obstructive Sleep Apnea (OSA). We are grateful to collaborate with leading healthcare institutions and experts in the region, who share our mission to transform the treatment of OSA and make sleep simple for patients worldwide."

With its growing network of centres across the Middle East, Nyxoah continues to deliver on its commitment to expand patient access to Genio, the only leadless, externally powered bilateral hypoglossal nerve stimulation system for the treatment of moderate-to-severe OSA.